Denali Therapeutics
Tracked across 3 events · 35 articles · First seen Apr 03, 2026 · Last active Jul 14, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Denali Therapeutics regained full rights to DNL593 after Takeda terminated their collaboration, allowing Denali Therapeutics to independently advance the therapy for FTD-GRN.
Apr 03, 2026 · 7 articles
Business
Impact: Denali Therapeutics Inc. sold its Rare Pediatric Disease Priority Review Voucher for $195 million, which will strengthen its financial flexibility and fund the advancement of its clinical pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases.
Jun 18, 2026 · 6 articles
Tech
Impact: Denali is developing transport vehicle technology to deliver Alzheimer's drugs across the blood-brain barrier, targeting tau and amyloid.
Jul 14, 2026 · 22 articles
ERGEN INTELLIGENCE
Track Denali Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard